Fulgent Genetics, Inc. (FLGT): Price and Financial Metrics

Fulgent Genetics, Inc. (FLGT): $39.49

0.15 (+0.38%)

POWR Rating

Component Grades








Add FLGT to Watchlist
Sign Up

FLGT Price/Volume Stats

Current price $39.49 52-week high $65.17
Prev. close $39.34 52-week low $28.27
Day low $39.11 Volume 229,100
Day high $40.16 Avg. volume 220,664
50-day MA $32.54 Dividend yield N/A
200-day MA $35.50 Market Cap 1.17B

FLGT Stock Price Chart Interactive Chart >


  • FLGT scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.9% of US stocks.
  • The strongest trend for FLGT is in Quality, which has been heading down over the past 179 days.
  • FLGT ranks lowest in Growth; there it ranks in the 3rd percentile.

FLGT Stock Summary

  • FLGT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 8.75% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, FULGENT GENETICS INC is reporting a growth rate of -106.06%; that's higher than merely 14.15% of US stocks.
  • Revenue growth over the past 12 months for FULGENT GENETICS INC comes in at -61.73%, a number that bests only 3.81% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to FULGENT GENETICS INC are LZ, LUNG, EVLV, DMTK, and BMRA.
  • Visit FLGT's SEC page to see the company's official filings. To visit the company's web site, go to www.fulgentgenetics.com.

FLGT Valuation Summary

  • In comparison to the median Healthcare stock, FLGT's price/sales ratio is 35.29% lower, now standing at 3.3.
  • Over the past 81 months, FLGT's EV/EBIT ratio has gone down 12.

Below are key valuation metrics over time for FLGT.

Stock Date P/S P/B P/E EV/EBIT
FLGT 2023-05-23 3.3 0.9 -46.1 -30.7
FLGT 2023-05-22 3.3 0.9 -46.0 -30.6
FLGT 2023-05-19 3.1 0.9 -43.3 -28.7
FLGT 2023-05-18 2.9 0.8 -40.8 -27.0
FLGT 2023-05-17 2.9 0.8 -40.9 -27.1
FLGT 2023-05-16 2.9 0.8 -41.3 -27.4

FLGT Growth Metrics

    Its 3 year price growth rate is now at 880.18%.
  • Its 2 year net income to common stockholders growth rate is now at 100459.91%.
  • The year over year price growth rate now stands at -27.12%.
FLGT's revenue has moved up $784,659,000 over the prior 70 months.

The table below shows FLGT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 802.935 297.399 271.574
2022-06-30 925.148 428.824 392.377
2022-03-31 953.423 493.809 460.652
2021-12-31 992.584 538.577 507.364
2021-09-30 1,035.891 595.747 569.332
2021-06-30 909.739 452.961 493.448

FLGT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FLGT has a Quality Grade of C, ranking ahead of 74.39% of graded US stocks.
  • FLGT's asset turnover comes in at 1.214 -- ranking 12th of 81 Healthcare stocks.
  • MGLN, UHS, and ADUS are the stocks whose asset turnover ratios are most correlated with FLGT.

The table below shows FLGT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.214 0.793 1.237
2021-03-31 1.514 0.793 1.595
2020-12-31 1.489 0.787 1.426
2020-09-30 1.037 0.692 0.646
2020-06-30 0.522 0.559 0.028
2020-03-31 0.472 0.565 -0.007

FLGT Price Target

For more insight on analysts targets of FLGT, see our FLGT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $103.00 Average Broker Recommendation 1.5 (Moderate Buy)

Fulgent Genetics, Inc. (FLGT) Company Bio

Fulgent Genetics, Inc., a technology company, focuses on providing genetic testing services to physicians with clinically actionable diagnostic information. It intends to provide tests to hospitals and medical institutions. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is based in Temple City, California.

FLGT Latest News Stream

Event/Time News Detail
Loading, please wait...

FLGT Latest Social Stream

Loading social stream, please wait...

View Full FLGT Social Stream

Latest FLGT News From Around the Web

Below are the latest news stories about FULGENT GENETICS INC that investors may wish to consider to help them evaluate FLGT as an investment opportunity.

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

EL MONTE, Calif., May 18, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Illinoi

Yahoo | May 18, 2023

3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened

There are reasons besides their cash positions to think these companies could see their stocks improve going forward.

Yahoo | May 8, 2023

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.

Yahoo | May 8, 2023

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2023

Fulgent Reports First Quarter 2023 Financial Results

EL MONTE, Calif., May 05, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.

Yahoo | May 5, 2023

Read More 'FLGT' Stories Here

FLGT Price Returns

1-mo 33.55%
3-mo 23.99%
6-mo 9.48%
1-year N/A
3-year 126.69%
5-year 961.56%
YTD 32.61%
2022 -70.39%
2021 93.07%
2020 303.88%
2019 306.94%
2018 -27.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!